ArticleResearch in pharmaceutical sciences2026
Computational investigation for exploring botanical ingredients as potential negative allosteric modulators targeting metabotropic glutamate receptor 5.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Metabotropic glutamate receptors are class C G-protein-coupled receptors that respond to the neurotransmitter glutamate. In particular, metabotropic glutamate receptor 5 (mGluR5) has been a valuable drug target for the management of psychiatric and neurodegenerative disorders such as fragile X syndrome, autism, depression, anxiety, addiction, and movement disorders through negative allosteric modulators (NAMs). Despite the discovery of several NAMs, limited clinical efficacy was observed, thus preventing them from reaching the clinical stage. Natural products are indispensable, with a plethora of pharmacological actions. This study aimed to identify potential natural compounds as novel natural NAMs modulating mGluR5 using a comprehensive Experimental approach: Utilizing receptor-based pharmacophore modelling, we virtually screened a natural library comprised of ~1.2 million compounds to study their molecular binding behavior against mGluR5. Furthermore, the best hits were evaluated using the end-point method (molecular mechanics Poisson-Boltzmann surface area), molecular dynamics (MD) simulations, and absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiling. Findings/Results: Based on the augmented computational modelling, we identified four promising natural hits-3'-HPS, gigantol, isorhapontigenin, and coclaurine that demonstrated higher affinities than the standard clinical candidate 2-methyl-6-phenylethynyl-pyridine (MPEP), and co-crystal 2-[2-(3-methoxyphenyl)ethynyl]-6-methyl-pyridine (M-MPEP). The top selected hits demonstrated optimal binding energies, molecular interactions, and favorable ADMET properties with a few toxicity liabilities, warranting further lead optimization and experimental validations. MD simulations validated their structural stability through RMSD, RMSF, and principal component analysis. Conclusion and implications: Our findings provided compelling evidence for a structure-based drug design approach in developing potent small-molecule natural modulators for the treatment of neurodegenerative disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.